425: Waters Corporation to Acquire BD's Biosciences & Diagnostic Solutions Business in $17.5 Billion Reverse Morris Trust

Waters Corporation announced a definitive agreement to acquire BD's Biosciences & Diagnostic Solutions business for approximately $17.5 billion through a Reverse Morris Trust, creating a combined entity with an expanded market presence and enhanced financial profile.

Summary

• Waters Corporation has agreed to acquire BD's Biosciences & Diagnostic Solutions business, valued at approximately $17.5 billion.
• Waters will issue 39.2% of its shares to BD shareholders and assume $4 billion of debt, with BD receiving $4 billion in cash distribution prior to closing.
• The combined company is expected to generate pro-forma revenue of about $6.5 billion and adjusted EBITDA of approximately $2 billion for 2025.
• R&D spend for the combined entity will be around 10% of product sales, supporting high-caliber innovation.
• The combination doubles Waters' total addressable market to approximately $40 billion, expanding into durable, volume-driven end markets growing 5-7% annually.
• Over 70% of the combined company's revenue will be annually recurring, enhancing growth stability and predictability.
• Significant synergies are expected: $200 million in annualized cost savings by year three and $290 million in annualized revenue synergies by year five post-closing.
• The deal is projected to be adjusted EPS accretive in year one, with midto high-single-digit annualized revenue growth and mid-teens adjusted EPS growth through the end of the decade.
• The combined company aims to expand its adjusted operating margin by approximately 500 basis points, reaching 32% by 2030.
• By 2030, the combined company expects to reach $9 billion in revenue and $3.3 billion in adjusted EBITDA.
• Net leverage is anticipated to reduce to below two times within 18 months, supported by strong free cash flow generation.
• BD Biosciences generated $1.5 billion in revenue in fiscal year 2024, addressing a $7 billion market, while BD Diagnostic Solutions delivered $1.8 billion in revenue, addressing a $15 billion market.
• Waters' total revenue in 2024 was around $3 billion, with EBITDA of $1.1 billion and an industry-leading adjusted operating margin of 31%.
• Waters has an installed base of over 170,000 systems, and BD has 75,000 instruments installed, with 20,000 due for replacement in the next two years.
• Waters plans to apply its proven commercial playbook, including instrument replacement, increasing service plan attachment (from BD's 40% to higher levels), and improving e-commerce adoption (from BD's 20% to over 50%).

Sentiment

Score: 9

Explanation: The document conveys a highly positive and confident outlook on the acquisition, emphasizing significant strategic fit, financial benefits, and growth opportunities. Management expresses strong excitement and belief in the value creation potential, with detailed projections for revenue, EPS, and margin expansion.

Positives

• Creates an innovation leader with robust financial strength, serving high-volume regulated applications with industry-leading brands.
• Significantly expands the total addressable market to approximately $40 billion, doubling Waters' previous TAM and adding breadth across end markets.
• Enhances growth stability with over 70% of revenue being annually recurring, smoothing out capital purchasing cycles.
• Supports an industry-leading financial outlook with projected midto high-single-digit revenue growth and mid-teens adjusted EPS growth.
• Expected to deliver significant cost synergies ($200 million by year three) and revenue synergies ($290 million by year five).
• The deal is expected to be adjusted EPS accretive in year one, with a rapid path to industry flagship margin levels (32% adjusted operating margin by 2030).
• Maintains a healthy and flexible balance sheet with rapid deleveraging supported by strong free cash flow generation.
• Offers an unparalleled strategic fit, accelerating Waters' entry into high-growth adjacencies like BioSeparations, Bioanalytical Characterizations, and Multiplex Diagnostics.
• Enables immediate commercial impact by applying Waters' proven execution playbook to BD's installed base of 75,000 instruments, including 20,000 due for replacement in the next two years.
• Leverages complementary customer bases and presents attractive cross-selling opportunities, such as tandem quad mass spectrometers into pharma drug metabolism and pharmacokinetics.
• BD Biosciences is an undisputed pioneer in flow cytometry, and BD Diagnostic Solutions is a pioneer in microbiology and clinical diagnostics, bringing iconic brands and strong innovation pipelines.
• Waters' expertise in downstream high-volume applications allows capturing growth in areas like biologics, GLP-1s, and generic off-patent therapeutics.
• The combination provides Waters with missing diagnostic infrastructure, regulatory and market access capabilities, global commercial reach, reagents, and automated sample prep for LC-MS in diagnostics.
• BD's localized manufacturing of the FACSLyric in China helps mitigate import bans and tariffs, positioning the business for stronger growth in the region.

Negatives

• Waters will assume $4 billion of debt as part of the transaction.
• The combined company's 2030 adjusted operating margin target of 32% is lower than Waters' standalone target of 35% previously communicated, though explained by mix and prudent assumptions.
• The BD Biosciences business has experienced a slowdown in academic and government spending, which is modeled for a slow recovery.
• BD's BACTEC business previously faced supply issues, which have now been resolved.
• The BD China business experienced challenges with importation of high-end flow business, which has also been resolved.

Risks

• One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
• Difficulties and delays may occur in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event could give rise to termination of the proposed transaction.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined operations.
• Changes in general economic and/or industry-specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• There is a risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Management time may be disrupted from ongoing business operations due to the pendency of the proposed transaction.
• The pendency of the proposed transaction could negatively affect the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.
• Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management.
• The credit ratings of the combined company could decline following the proposed transaction.
• The announcement or the consummation of the proposed transaction could have a negative effect on the market price of the capital stock of Waters and BD or on Waters and BD's operating results.

Future Outlook

The combined company is projected to achieve midto high-single-digit annualized revenue growth and mid-teens adjusted EPS growth through the end of the decade. It expects to expand its adjusted operating margin by approximately 500 basis points over five years, reaching 32% by 2030, and aims for $9 billion in revenue and $3.3 billion in adjusted EBITDA by 2030. Net leverage is expected to be reduced to below two times within 18 months.

Management Comments

• We are thrilled to announce today that Waters has agreed to issue 39.2% of its shares to BD shareholders and assume $4 billion of debt to acquire the BD Biosciences & Diagnostic Solutions business.
• This is a rare and powerful opportunity to unite two industry leaders with complementary capabilities, a legacy of pioneering science and a shared, deep-rooted culture of innovation.
• This combination positions us to deliver exceptional long-term benefits for customers and shareholders by uniting Waters leadership in downstream analytical workflows with BDs strength in cellular analysis and diagnostics.
• This combination more than doubles Waters total addressable market to 40 billion, up from 19 billion TAM. It also adds greater breadth across end markets and applications reducing dependency on any single segment.
• The combination is expected to deliver midto high-single-digit revenue growth, mid-teens adjusted EPS growth, as well as rapid EPS accretion and leading cash flow generation.
• We believe this transaction represents both a tremendous outcome for the Biosciences & Diagnostic Solutions business and creates significant value for shareholders.
• Ultimately, we determined that an RMT with Waters is the ideal structure to immediately unlock value for BD shareholders and create a unique opportunity to participate in the upside of the combined company.
• With Waters operational focus, execution playbook, deep life sciences expertise, highly complementary portfolio, and strong commitment to innovation, we see a step-change opportunity ahead to unlock the full potential of Biosciences & Diagnostics.
• At Waters, we too have built a highly repeatable business model centered around downstream regulated applications where high throughput, compliance, and reliability are critical.
• We expect approximately $200 million of annualized cost synergies by year three post-closing... We are also very confident that we can deliver approximately $290 million of annualized revenue synergies by year five post-closing.
• The combined company is positioned to deliver a compelling compounded growth profile over the next five years that investors can believe in.
• The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, Waters shareholder approval, and satisfaction of other customary closing conditions.
• This transaction is not just additive, it is transformational. It creates a life science and diagnostic leader with a strong foundation and a clear focus built to shape the future of regulated science and deliver meaningful value to shareholders, customers, and employees alike.
• The momentum on the business remains really strong. Today is about the deal, so lets focus on that today. Three weeks from now, I promise we will give you all the details that you want on the earnings. I can just say the momentum remains strong.
• What people love about Waters is the quality of the asset Waters is, and this business that we are inheriting is exactly that. BD pioneered flow. It has supported Nobel Prize-winning research.
• The underlying Waters margin profile that we communicated on the Investor Day really doesnt change. The assumptions we are making on BDs standalone business are pretty prudent, and gives us a meaningful upside potential if we are able to execute all the programs that were inheriting from BD on margin expansion well.

Industry Context

This acquisition signifies a major consolidation and strategic expansion within the life science tools and diagnostics industry. It creates a diversified leader focused on high-volume, regulated applications, a segment known for its stability and recurring revenue. The move positions Waters to compete more broadly in cellular analysis and diagnostics, leveraging its expertise in analytical workflows and BD's established presence and innovation in flow cytometry and microbiology. The emphasis on recurring revenue and stable growth drivers like pill count and infection rates reflects a broader industry trend towards more resilient business models less susceptible to discretionary capital spending cycles. The focus on high-growth adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics indicates a strategic push into areas with significant unmet needs and growth potential, aligning with advancements in biologics, cell therapy, and early disease detection.

Comparison to Industry Standards

• The combined company's projected R&D spend at 10% of product sales is described as 'industry-leading'.
• The target of 32% adjusted operating margin by 2030 is stated to place the combined company 'at the top of the sector' and achieve 'industry flagship margin levels'.
• Waters' standalone organic growth, adjusted EBITDA margin, and free cash flow as a percentage of revenue have been 'well above the peer group average'.
• BD Biosciences is described as the 'undisputed pioneer' in flow cytometry, having invented the modern field.
• BD Diagnostic Solutions is a 'pioneer' in microbiology research and clinical diagnostics with multiple world firsts.
• The combined company's projected midto high-single-digit revenue CAGR growth and mid-teens adjusted EPS CAGR growth over five years are stated to 'set us apart from our peers'.
• Waters' Empower platform is used for approximately 80% of novel drugs submitted to the FDA, EMA, and China NMPA, indicating a dominant position in its niche.
• Companies with antibody portfolios usually have e-commerce penetration between 50% and 75%, suggesting significant headroom for BD's current 20% penetration.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders of Waters are expected to benefit from significant long-term value creation, mid-teens adjusted EPS growth, rapid EPS accretion, and participation in an expanded market with a more resilient growth profile.
• Shareholders of BD will receive 39.2% of Waters' shares, allowing them to participate in the upside of the combined company, while BD itself will become a pure-play med tech leader with enhanced focus.
• Customers are expected to benefit from broader capabilities, best-in-class technologies, accelerated innovation in high-growth areas, and potentially improved service offerings, such as 24-hour premier service.
• The combined company will have approximately 16,000 employees, with management expressing confidence in ensuring employees continue their legacy of delivering innovative solutions, though there is a risk of inability to retain and hire key personnel.
• Suppliers may be impacted by efforts to optimize manufacturing and supply chain, and consolidate procurement volumes, contributing to cost synergies.
• Creditors will see Waters assume $4 billion of debt, but the company expects rapid deleveraging to below two times net leverage within 18 months, supported by strong free cash flow generation.

Next Steps

• Waters intends to file a registration statement on Form S-4 with the SEC, which will include a preliminary and definitive proxy statement/prospectus.
• Augusta SpinCo Corporation (SpinCo) intends to file a registration statement on Form 10 with the SEC.
• Receipt of required regulatory approvals for the transaction.
• Waters shareholder approval for the transaction.
• Satisfaction of other customary closing conditions.
• The transaction is expected to close around the end of the first quarter of calendar year 2026.
• Waters will hold its second quarter financial results earnings call on August 4th.
• Integration of BD Biosciences & Diagnostic Solutions business into Waters' operations.
• Deployment of Waters' proven commercial playbook (instrument replacement programs, service plan attachment, e-commerce adoption) to BD's installed base and consumables portfolio.
• Acceleration of innovation in high-growth adjacencies: BioSeparations, Bioanalytical Characterizations, and Multiplex Diagnostics.
• Continued investment in R&D at 10% of product sales for the combined company.
• Reduction of net leverage to below two times within 18 months post-closing.

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Biosciences, Diagnostic Solutions, Reverse Morris Trust, Acquisition, Merger, Life Science Tools, Flow Cytometry, Microbiology, Diagnostics, Analytical Instruments, Mass Spectrometry, Liquid Chromatography, Laboratory Automation, Healthcare, Biotechnology, Pharma, Biopharma, Regulated Markets, Recurring Revenue, Synergies, Financial Outlook, R&D, Corporate Governance, SEC Filing